Metabolic and therapeutic effects of insulin-like growth factor I

E. R. Froesch, P. D. Zenobi, Mehboob Hussain

Research output: Contribution to journalArticle

Abstract

The administration of rhIGF-I in appropriate doses leads to a decrease of insulin and growth hormone secretion and to an increase of insulin sensitivity. In type 2 diabetic patients, IGF-I improves glyceinic profiles. In normal subjects, IGF-I increases energy expenditure and lipid oxidation and has a protein- sparing effect. Total and VLDL-triglycerides as well as LDL-cholesterol are decreased by IGF-I administration. This metabolic profile of IGF-I allows speculation on its possible usefulness in conditions of relative insulin resistance often associated with increased cardiovascular morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)66-71
Number of pages6
JournalHormone Research in Paediatrics
Volume42
Issue number1-2
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Therapeutic Uses
Insulin-Like Growth Factor I
Insulin Resistance
Metabolome
LDL Cholesterol
Energy Metabolism
Growth Hormone
Insulin
Morbidity
Lipids
Mortality
Proteins

Keywords

  • Growth hormone inhibition
  • Insulin inhibition
  • Insulin sensitivity
  • Lipid metabolism
  • rhIGF-I therapy

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Metabolic and therapeutic effects of insulin-like growth factor I. / Froesch, E. R.; Zenobi, P. D.; Hussain, Mehboob.

In: Hormone Research in Paediatrics, Vol. 42, No. 1-2, 1994, p. 66-71.

Research output: Contribution to journalArticle

Froesch, E. R. ; Zenobi, P. D. ; Hussain, Mehboob. / Metabolic and therapeutic effects of insulin-like growth factor I. In: Hormone Research in Paediatrics. 1994 ; Vol. 42, No. 1-2. pp. 66-71.
@article{03ff9f887e90493eacd7df826821bfde,
title = "Metabolic and therapeutic effects of insulin-like growth factor I",
abstract = "The administration of rhIGF-I in appropriate doses leads to a decrease of insulin and growth hormone secretion and to an increase of insulin sensitivity. In type 2 diabetic patients, IGF-I improves glyceinic profiles. In normal subjects, IGF-I increases energy expenditure and lipid oxidation and has a protein- sparing effect. Total and VLDL-triglycerides as well as LDL-cholesterol are decreased by IGF-I administration. This metabolic profile of IGF-I allows speculation on its possible usefulness in conditions of relative insulin resistance often associated with increased cardiovascular morbidity and mortality.",
keywords = "Growth hormone inhibition, Insulin inhibition, Insulin sensitivity, Lipid metabolism, rhIGF-I therapy",
author = "Froesch, {E. R.} and Zenobi, {P. D.} and Mehboob Hussain",
year = "1994",
doi = "10.1159/000184148",
language = "English (US)",
volume = "42",
pages = "66--71",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "1-2",

}

TY - JOUR

T1 - Metabolic and therapeutic effects of insulin-like growth factor I

AU - Froesch, E. R.

AU - Zenobi, P. D.

AU - Hussain, Mehboob

PY - 1994

Y1 - 1994

N2 - The administration of rhIGF-I in appropriate doses leads to a decrease of insulin and growth hormone secretion and to an increase of insulin sensitivity. In type 2 diabetic patients, IGF-I improves glyceinic profiles. In normal subjects, IGF-I increases energy expenditure and lipid oxidation and has a protein- sparing effect. Total and VLDL-triglycerides as well as LDL-cholesterol are decreased by IGF-I administration. This metabolic profile of IGF-I allows speculation on its possible usefulness in conditions of relative insulin resistance often associated with increased cardiovascular morbidity and mortality.

AB - The administration of rhIGF-I in appropriate doses leads to a decrease of insulin and growth hormone secretion and to an increase of insulin sensitivity. In type 2 diabetic patients, IGF-I improves glyceinic profiles. In normal subjects, IGF-I increases energy expenditure and lipid oxidation and has a protein- sparing effect. Total and VLDL-triglycerides as well as LDL-cholesterol are decreased by IGF-I administration. This metabolic profile of IGF-I allows speculation on its possible usefulness in conditions of relative insulin resistance often associated with increased cardiovascular morbidity and mortality.

KW - Growth hormone inhibition

KW - Insulin inhibition

KW - Insulin sensitivity

KW - Lipid metabolism

KW - rhIGF-I therapy

UR - http://www.scopus.com/inward/record.url?scp=0027932692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027932692&partnerID=8YFLogxK

U2 - 10.1159/000184148

DO - 10.1159/000184148

M3 - Article

C2 - 7959637

AN - SCOPUS:0027932692

VL - 42

SP - 66

EP - 71

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 1-2

ER -